Clinical-stage biopharmaceutical company Hoth Therapeutics Inc (NASDAQ:HOTH) announced on Wednesday an expansion of its intellectual property portfolio for HT-001, its lead topical therapeutic candidate, in the United States.

Hoth has filed multiple US Provisional Patent Applications covering novel dermatological indications, expanding the commercial and clinical potential of HT-001. The filings cover treatment of Drug-Induced Hypersensitivity Syndrome, Radiotherapy-Induced Rash, and Dermatological Conditions Associated with MENIN Inhibitor Therapy.

MENIN inhibitors are an emerging class of targeted oncology drugs that can induce strong anti-tumour activity. However, patients often experience significant dermatological side effects, including painful or disfiguring rashes that can lead to dose reductions or treatment discontinuation. These adverse events may limit the full therapeutic potential of MENIN inhibitor therapy.

HT-001's novel topical formulation is designed to address these dermatological toxicities directly, offering patients relief from rash and skin irritation without hindering their cancer treatment.

Currently, the product is being advanced as a topical therapeutic for chemotherapy-induced rash, a dose-limiting side effect impacting patients receiving EGFR inhibitors and other targeted therapies. The patent filings expand the potential utility of the product to additional drug-induced and treatment-related skin disorders.